ER-100: The First Human Data on Epigenetic Reprogramming

Life Biosciences has shared the first human data for ER-100, a partial epigenetic reprogramming gene therapy, from a phase 1 study in three patients with glaucoma.

For years, partial epigenetic reprogramming has been one of the most talked-about ideas in longevity science. The idea is to use a small set of genes to reset patterns of gene activity in cells. Most of what we have known about it has come from the lab. On 8 October 2026, that changed. Life Biosciences presented first-in-human data from its ongoing phase 1 trial of ER-100, its partial epigenetic reprogramming therapy.

The results come from a very small, early study. They show that the approach can be tested in people, not that it works. Here is what was done, what was found, what the data can't tell us and what happens next.

What is ER-100?

ER-100 is a gene therapy developed by Life Biosciences. It is built on three of the so-called Yamanaka factors: OCT4, SOX2 and KLF4, often shortened to OSK. These are transcription factors, proteins that control which genes are switched on in a cell. According to Life Biosciences' announcement, ER-100 uses controlled expression of these three factors.

The key word is partial. The approach targets the epigenetic state of cells, the layer of chemical marks that influences how genes are read.

The expression of the three factors is controlled with doxycycline. The genes are only switched on while doxycycline is given, which lets researchers decide how long the reprogramming signal stays on.

How the study worked

The data presented on 8 October come from three patients with glaucoma, a disease that affects the optic nerve and the visual field. According to Life Biosciences, each patient received a single injection of ER-100 in the eye. Gene expression was then switched on for eight weeks (56 days) with doxycycline.

This is a phase 1 study. Phase 1 trials are designed first and foremost to study safety and tolerability, which is why the main readout concerns how the treatment was tolerated. The researchers also measured visual field, a standard eye test that measures how well a person detects light across many points in their field of vision, scored in decibels.

The results

The results were reported after 56 days.

Safety. In Life Biosciences' announcement, ER-100 was tolerated in all three patients through Day 56, with no reported serious side effects. For a first-in-human study of a new kind of therapy, safety is the main question, but three patients over 56 days is far too few and too short to rule out rarer or later side effects.

Visual field. Two of the three patients improved on visual field testing at Day 56 (source).

Size of the change. In each of those two patients, at least 28% of the tested visual field points improved by more than 4 decibels (source).

Why it matters for longevity

Partial epigenetic reprogramming is one of the most discussed ideas in longevity research: that some age-related changes in cells could be reset rather than just slowed down. Until now, the evidence has come from cells and animals. ER-100 has now produced the first early human data of this kind.

The announcement suggests that a partial reprogramming therapy built on OCT4, SOX2 and KLF4 can be given to a small number of people, switched on for eight weeks and followed with standard clinical tests. The eye is a practical place to start. Glaucoma has clear, measurable outcomes, such as visual field testing, and the treatment can be delivered locally with a single injection.

It does not show that reprogramming slows or reverses aging in people, and it says nothing about use outside the eye.

Read: Epigenetic age tests: what they measure and miss →

Limitations: what this data can't tell us

Three patients. With so few people, chance and individual variation can easily explain the results in either direction.
No control group. All three patients received ER-100. Without a placebo or untreated comparison group, it is not possible to say how much of the visual field change was caused by the treatment.
Interim, short-term data. The trial is ongoing and the results cover 56 days. Visual field tests can vary from one test to the next, and it is not yet known whether any change lasts.
Press release, not peer review. The data come from the company's own announcement and have not yet been published in a peer-reviewed journal.
One mixed result. One of the three patients did not improve on visual field testing.

What happens next

According to Life Biosciences, the independent safety committee overseeing the trial (a Data Safety Monitoring Board) recommended moving the next patient group to a higher dose. The next dose level is three times higher than the first, and the trial is ongoing.

The next group of patients, at a three times higher dose, will add more data on how ER-100 is tolerated and how visual field results develop.

Also this week

Two other studies in Nature Aging this week add to the picture of how aging works at the level of cells and tissues.

Longer lipid chains with age. A study published in Nature Aging on 6 October 2026, "Longer lipids mark aging and constrain lifespan", found that the fatty acid chains in cell lipids get longer with age in humans, mice, fruit flies and roundworms. In humans, a similar lengthening was linked to the development of heart disease. The researchers identified the enzyme Plb1 as a regulator of this process. Lowering the corresponding enzyme in roundworms gave shorter chains and a longer lifespan, which makes it a possible new drug target.

Thymus and immune aging in male mice. A study published in Nature Aging on 9 October 2026, "Lymph node contraction links sex-biased naive CD8+ T cell decline to compromised antigen recognition during middle age", found that male mice lose naive CD8+ T cells faster than females, as the thymus shrinks with age. Androgen blockade in middle-aged male mice increased naive T cells, restored parts of lymph node function, improved cancer recognition and improved the effect of immunotherapy. Supporting human data included the Swedish SCAPIS study. The effects were shown in mice.

The bottom line

ER-100 has produced the first human data on partial epigenetic reprogramming: three patients with glaucoma, a single injection in the eye, eight weeks of gene expression, no reported serious side effects after 56 days and visual field improvements in two of three patients. These are early, uncontrolled results from a company press release, so they are a reason to keep watching, not proof that the therapy works. The next group will receive a three times higher dose.

Want to build your own healthspan routine while the science moves forward? Start with the Foundations protocol.

This article is for information only and is not medical advice.